Recommended Treatment Schedules
Prevention of rheumatic fever requires eradication of Group A streptococci from the throat. Treatment should begin as soon as a definite diagnosis of Group A streptococcal infection is made (see Table  1 ). Penicillin, even when started several days after onset of acute illness, effectively prevents primary attacks of rheumatic fever; however, early diagnosis and therapy may reduce the period of infectivity used, they should contain benzathine penicillin G in the following doses:
The recommended dosage of benzathine penicillin G is 600,000 units intramuscularly for patients weighing 60 lb (27 kg) or less, and 1,200,000 units for patients weighing more than 60 lb. The combination of 900,000 units of benzathine penicillin G and 300,000 units of procaine penicillin G may be satisfactory in many smaller patients, but this dosage is based on limited data. The efficacy of this combination for heavier patients such as teenagers or adults requires further study.
Oral Penicillin
The oral antibiotic of choice is penicillin V. Dosage for both children and adults is 250 mg, three times daily for 10 days. It is important to emphasize that patients should continue to take penicillin regularly for the entire 10-day period, even though they will likely be asymptomatic after the first few days. In contrast, patients who have not had rheumatic carditis are at considerably less risk of cardiac involvement with a recurrence. Therefore, a physician may wish to discontinue prophylaxis in these patients after several years. In general, prophylaxis should continue until the patient is in his or her early 20s and five years have elapsed since the last rheumatic attack. The decision to continue prophylaxis should be made after discussion with the patient of potential risks and benefits and careful consideration of the epidemiological risk factors enumerated above. Choice of Program for Prevention of Recurrent Rheumatic Fever Intramuscular Benzathine Penicillin G An injection of 1,200,000 units of this long-acting penicillin preparation every four weeks is the recommended method of secondary prevention. In countries where incidence of acute rheumatic fever is particularly high, or in certain high-risk patients, use of benzathine penicillin G every three weeks may be warranted. Long-acting penicillin is of particular value in patients with a high risk of rheumatic fever recurrence, especially those with rheumatic heart disease in whom recurrence is more dangerous. In each patient, the advantages of benzathine penicillin G must be weighed against inconvenience to the patient and pain of injection, which may cause some patients to discontinue prophylaxis. Oral Agents Successful oral prophylaxis depends primarily on patient compliance. Patients need careful and repeated instructions about the importance of continuing prophylaxis. Note: Allergic reactions to penicillin are more common in adults than children. They occur in only a small percentage of patients, are more frequent after injection, and include urticaria and angioneurotic edema. A serum sickness-like reaction characterized by fever and joint pains may be mistaken for acute rheumatic fever. As with all penicillins, anaphylaxis, although rare, may occur. A careful history for allergic reactions to penicillin should be obtained.
Other Drugs. For the exceptional patient who may be allergic to both penicillin and sulfonamides, erythromycin may be used. An appropriate dose has not been established, but 250 mg twice daily is suggested.
Bacterial Endocarditis Prophylaxis
Patients with evidence of rheumatic valvular heart disease also require additional short-term antibiotic prophylaxis before some surgical and dental procedures to prevent possible development of bacterial endocarditis. Antibiotic regimens used to prevent recurrences of acute rheumatic fever are inadequate for prevention of bacterial endocarditis. These patients should be protected by administration of appropriate antibiotics in recommended doses. Patients with prosthetic valves are at particularly high risk. The current recommendations of the American Heart Association concerning prevention ofbacterial endocarditis should be followed. Patients who have had rheumatic fever but do not have evidence of rheumatic heart disease do not need endocarditis prophylaxis.
Special Problems
There is uncertainty about the most appropriate management of treatment failures, chronic carriers, and contacts.
Treatment Failures
Failure to eradicate Group A streptococci from the throat usually occurs more frequently after oral antibiotic treatment than after administration of intramuscular benzathine penicillin G. Streptococcal carriers appear to pose little threat to themselves in developing sequelae of streptococcal infection, or in disseminating the organism to those who live and work around them. Therefore, streptococcal carriers usually do not need to be identified or treated.
Asymptomatic Contacts
In most circumstances, identification and treatment of asymptomatic household contacts are not indicated. However, in households with a rheumatic individual, or special epidemiological circumstances, it is advisable to obtain cultures and treat those with positive cultures.
